The clinical efficacy of medetomidine.
Studies on the clinical efficacy of medetomidine, a novel alpha-2 adrenoceptor agonist, are reviewed. Medetomidine has been shown to produce a reliable state of sedation, relaxation and recumbency suitable for small animal practice. In dogs, the optimal clinical dose for examinations, clinical procedures and minor surgical interventions seems to be 30-40 micrograms/kg intramusculary and in cats 80-110 micrograms/kg. Other effects of medetomidine reported include bradycardia, nausea and vomiting. Occasional muscle jerkings have been also reported after medetomidine injection. In special investigations, medetomidine has successfully been used in wound suturation and ovariohysterectomy in dogs and for sedation in dogs with heart diseases. Medetomidine-ketamine combination has been shown to be useful for anesthesia and immobilization in cats and zoo animals. The medetomidine-fentanyl combination was tested in dog: The administration of fentanyl increased the sedation and analgesia obtained with medetomidine. Medetomidine appears to be a potent sedative and analgesic agent for clinical use.
Vähä-Vahe
T
T
D000316:Adrenergic alpha-Agonists / Q000009:adverse effects / Q000494:pharmacology*; D000700:Analgesics; D000818:Animals; D002986:Clinical Trials as Topic / Q000662:veterinary; D004359:Drug Therapy, Combination; D006993:Hypnotics and Sedatives; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology*; D020926:Medetomidine
D000316:Adrenergic alpha-Agonists; D000700:Analgesics; D006993:Hypnotics and Sedatives; D007093:Imidazoles; D020926:Medetomidine